447 reports of this reaction
3.7% of all RAMELTEON reports
#2 most reported adverse reaction
INITIAL INSOMNIA is the #2 most commonly reported adverse reaction for RAMELTEON, manufactured by Takeda Pharmaceuticals America, Inc.. There are 447 FDA adverse event reports linking RAMELTEON to INITIAL INSOMNIA. This represents approximately 3.7% of all 11,977 adverse event reports for this drug.
Patients taking RAMELTEON who experience initial insomnia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
INITIAL INSOMNIA is moderately reported among RAMELTEON users, representing a notable but not dominant share of adverse events.
In addition to initial insomnia, the following adverse reactions have been reported for RAMELTEON:
The following drugs have also been linked to initial insomnia in FDA adverse event reports:
INITIAL INSOMNIA has been reported as an adverse event in 447 FDA reports for RAMELTEON. This does not prove causation, but indicates an association observed in post-market surveillance data.
INITIAL INSOMNIA accounts for approximately 3.7% of all adverse event reports for RAMELTEON, making it one of the most commonly reported side effect.
If you experience initial insomnia while taking RAMELTEON, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.